Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04846478 · ClinicalTrials.gov registry record · Phase 1

Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC

A Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
Phase 1
Development phase
35
Enrollment target
2
Study locations

NCT04846478 is a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 35 participants, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (82% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04846478, a Phase 1 study of Metastatic Castration-Resistant Prostate Cancer and Metastatic Prostate Cancer, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
Phase 1
Development phase
35 participants
Enrollment target
2
Study locations

Study Summary

This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study drugs involved in this study are: * Talazoparib * Tazemetostat

Conditions Studied

Metastatic Castration-Resistant Prostate Cancer Metastatic Prostate Cancer

Interventions

  • DRUG Talazoparib
  • DRUG Tazemetostat

Study Locations (2)

Massachusetts

  • Brigham and Women's Hospital - Boston
  • Dana Farber Cancer Institute - Boston

Trial Details

FieldValue
Enrollment Target 35 participants
Start Date 2021-06-28
Est. Completion 2026-09-30
Phase Phase 1

Sponsor

Dana-Farber Cancer Institute

781 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04846478

The ClinicalTrials.gov registry entry for NCT04846478 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 197-participant average among 69 other Metastatic Castration-Resistant Prostate Cancer trials with a reported enrollment target (82% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Castration-Resistant Prostate Cancer appearing as the primary indexed condition, and to 2 interventions - of which Talazoparib is the first listed.

NCT04846478 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04846478 about?

NCT04846478 is a clinical study titled "Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC". This trial is testing whether molecularly targeted oral medications called talazoparib and tazemetostat can be safely combined for the treatment of prostate cancer, and whether the combination is effective in shrinking or preventing the growth of metastatic prostate cancer. The names of the study d...

What is the current status of trial NCT04846478?

This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2021-06-28. Estimated completion is 2026-09-30.

What conditions does trial NCT04846478 study?

This clinical trial studies the following conditions: Metastatic Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer.

What interventions are being tested in trial NCT04846478?

The interventions under investigation include: Talazoparib (DRUG), Tazemetostat (DRUG).

Who is sponsoring clinical trial NCT04846478?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04846478 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Castration-Resistant Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Metastatic Castration-Resistant Prostate Cancer

All registered trials for this condition

Metastatic Prostate Cancer

All registered trials for this condition

Massachusetts

All trials with a study site in Massachusetts

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.